{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:00Z","timestamp":1793159100988,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives and background<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12\u00a0months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with confirmed ATTR-CM (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200956) were divided into two groups: in the larger group A (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200939; 95% male), treatment with tafamidis 61\u00a0mg once daily was initiated after the first CMR study, whereas group B (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200917; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27\u2009\u00b1\u20096\u00a0months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-na\u00efve group B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48%\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 vs 56% to 46%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; \u22127.4 to \u22125.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 vs \u22128.8 to \u22124.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, the tafamidis-na\u00efve group B experienced a substantially higher impairment of both parameters when compared to group A (\u2206p\u2009=\u20090.008 and \u2206p\u2009=\u20090.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-na\u00efve group B (from 18.2\u00a0mm to 21.1\u00a0mm at follow-up,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to the tafamidis-treated group A (from 18.5\u00a0mm to 19.2\u00a0mm, p\u2009=\u20090.012; \u2206\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Both global native T1 and global ECV values were significantly elevated in both groups\u2014at baseline and at follow-up\u2014with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-na\u00efve group B compared to the tafamidis-treated group A (group A: 51% to 57%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; group B: 50% to 67%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; \u2206p\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-na\u00efve ATTR-CM patients within a follow-up period of approximately 2\u00a0years. However, the \u201cextent of worsening\u201d is significantly lower in the tafamidis-treated compared to the tafamidis-na\u00efve patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02691-8","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:27:24Z","timestamp":1761553644000},"page":"785-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis"],"prefix":"10.1007","volume":"115","author":[{"given":"Alexandru","family":"Zlibut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bietenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye","family":"Akyol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vehof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Bouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuraman","family":"Isgandarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Theofanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Stalling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-8679","authenticated-orcid":false,"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"11","key":"2691_CR1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH (2023) 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 81(11):1076\u20131126","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2691_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz A, Bauersachs J, Bengel F, Buchel R, Kindermann I, Klingel K, Knebel F, Meder B, Morbach C, Nagel E, Schulze-Bahr E, dem Aus SF, Frey N (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479\u2013506","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2691_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26216-9","volume":"12","author":"B Chamling","year":"2022","unstructured":"Chamling B, Bietenbeck M, Drakos S, Korthals D, Vehof V, Stalling P, Meier C, Yilmaz A (2022) A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis. Sci Rep 12(1):21755","journal-title":"Sci Rep"},{"issue":"22","key":"2691_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, Bandera F, Masi A, Williams GE, O\u2019Beara S, Ganesananthan S, Massa P, Knight D, Martinez-Naharro A, Kotecha T, Chacko L, Brown J, Rauf MU, Manisty C, Moon J, Lachmann H, Wechelakar A, Petrie A, Whelan C, Hawkins PN, Gillmore JD, Fontana M (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146(22):1657\u20131670","journal-title":"Circulation"},{"key":"2691_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.10.011","author":"M Fontana","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, Dorbala S, Masri A, Moon JC, Singh V, Clerc O, Hanna M, Ruberg F, Grogan M, Emdin M, Gillmore J (2025) The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response. JACC Cardiovasc Imaging. https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2691_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00392-020-01771-1","volume":"110","author":"G Chatzantonis","year":"2021","unstructured":"Chatzantonis G, Bietenbeck M, Elsanhoury A, Tschope C, Pieske B, Tauscher G, Vietheer J, Shomanova Z, Mahrholdt H, Rolf A, Kelle S, Yilmaz A (2021) Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 110(4):555\u2013568","journal-title":"Clin Res Cardiol"},{"issue":"24","key":"2691_CR7","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","volume":"44","author":"MU Rauf","year":"2023","unstructured":"Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, Petrie A, Law S, Porcari A, Razvi Y, Bomsztyk J, Ravichandran S, Ioannou A, Patel R, Starr N, Hutt DF, Mahmood S, Wisniowski B, Martinez-Naharro A, Venneri L, Whelan C, Roczenio D, Gilbertson J, Lachmann HJ, Wechalekar AD, Rapezzi C, Serenelli M, Massa P, Caponetti AG, Ponziani A, Accietto A, Giovannetti A, Saturi G, Sguazzotti M, Gagliardi C, Biagini E, Longhi S, Fontana M, Gillmore JD (2023) Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J 44(24):2187\u20132198","journal-title":"Eur Heart J"},{"issue":"1","key":"2691_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94650-2","volume":"11","author":"D Korthals","year":"2021","unstructured":"Korthals D, Chatzantonis G, Bietenbeck M, Meier C, Stalling P, Yilmaz A (2021) CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci Rep 11(1):15521","journal-title":"Sci Rep"},{"issue":"11","key":"2691_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"1","key":"2691_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, Maurer MS, Boman K, Gundapaneni B, Sultan MB, Elliott P (2024) Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol 9(1):25\u201334","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2691_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","volume":"112","author":"B Chamling","year":"2023","unstructured":"Chamling B, Bietenbeck M, Korthals D, Drakos S, Vehof V, Stalling P, Meier C, Yilmaz A (2023) Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol 112(3):353\u2013362","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"2691_CR12","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/ehf2.14815","volume":"11","author":"S Dobner","year":"2024","unstructured":"Dobner S, Bernhard B, Ninck L, Wieser M, Bakula A, Wahl A, Kochli V, Spano G, Boscolo BM, Elchinova E, Safarkhanlo Y, Stortecky S, Schutze J, Shiri I, Hunziker L, Grani C (2024) Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC Heart Fail 11(5):2759\u20132768","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2691_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ehjci\/jead188","volume":"25","author":"F Duca","year":"2023","unstructured":"Duca F, Rettl R, Kronberger C, Binder C, Mann C, Dusik F, Schrutka L, Dalos D, Ozturk B, Dachs TM, Cherouny B, Camuz LL, Agis H, Kain R, Koschutnik M, Dona C, Badr-Eslam R, Kastner J, Beitzke D, Loewe C, Nitsche C, Hengstenberg C, Kammerlander AA, Bonderman D (2023) Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry. Eur Heart J Cardiovasc Imaging 25(1):95\u2013104","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"2691_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","volume":"17","author":"Y Razvi","year":"2024","unstructured":"Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, Gillmore JD, Kellman P, Edwards L, Taubel J, Du J, Tamby JF, Castano A, Siddhanti S, Katz L, Fox JC, Fontana M (2024) Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy. Circ Heart Fail 17(12):e012135","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2691_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/ehjci\/jeae021","volume":"25","author":"J Cotella","year":"2024","unstructured":"Cotella J, Randazzo M, Maurer MS, Helmke S, Scherrer-Crosbie M, Soltani M, Goyal A, Zareba K, Cheng R, Kirkpatrick JN, Yogeswaran V, Kitano T, Takeuchi M, Fernandes F, Hotta VT, Campos Vieira ML, Elissamburu P, Ronderos R, Prado A, Koutroumpakis E, Deswal A, Pursnani A, Sarswat N, Addetia K, Mor-Avi V, Asch FM, Slivnick JA, Lang RM (2024) Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. Eur Heart J Cardiovasc Imaging 25(6):754\u2013761","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, dem Aus SF, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T (2023) Phase 1 trial of antibody ni006 for depletion of cardiac transthyretin amyloid. N Engl J Med 389(3):239\u2013250","journal-title":"N Engl J Med"},{"issue":"1","key":"2691_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, Gonzalez-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt PS, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392(1):33\u201344","journal-title":"N Engl J Med"},{"issue":"1","key":"2691_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, Strehina S, Lane T, Moon J, Hutt DF, Kellman P, Petrie A, Hawkins PN, Gillmore JD (2021) Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 14(1):189\u2013199","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02691-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:55:32Z","timestamp":1776236132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02691-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complies with the Declaration of Helsinki. Ethics approval was obtained from the local authorities (Ethikkommission der \u00c4rztekammer Westfalen-Lippe; ID 2019\u2013437-f-S) and written informed consent was obtained from the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}